5414x 🔥 🎯

The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights:

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion . The full text and detailed report of this

: £13.0 million (+52.9%), driven by AMR and EMEAI growth. : £72

: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards. Interim results for the 6 months ended 30

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year.

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments